Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC trimmed its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 9.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,245 shares of the company’s stock after selling 4,850 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Moderna were worth $4,400,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Redwood Wealth Management Group LLC boosted its stake in shares of Moderna by 15.7% in the 4th quarter. Redwood Wealth Management Group LLC now owns 3,132 shares of the company’s stock valued at $311,000 after buying an additional 425 shares during the period. Bristlecone Advisors LLC grew its holdings in Moderna by 2.6% during the 4th quarter. Bristlecone Advisors LLC now owns 5,999 shares of the company’s stock worth $597,000 after acquiring an additional 153 shares in the last quarter. 180 Wealth Advisors LLC increased its position in shares of Moderna by 1.9% in the 4th quarter. 180 Wealth Advisors LLC now owns 14,033 shares of the company’s stock valued at $1,396,000 after purchasing an additional 266 shares during the last quarter. Arlington Trust Co LLC raised its holdings in shares of Moderna by 4,833.3% in the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after purchasing an additional 290 shares in the last quarter. Finally, Cubic Asset Management LLC lifted its position in shares of Moderna by 21.7% during the 4th quarter. Cubic Asset Management LLC now owns 3,925 shares of the company’s stock worth $390,000 after purchasing an additional 700 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently commented on MRNA. Jefferies Financial Group reissued a “buy” rating and issued a $125.00 target price on shares of Moderna in a report on Tuesday, April 9th. HSBC reissued a “reduce” rating and set a $86.00 target price (up previously from $75.00) on shares of Moderna in a research report on Monday, February 26th. Canaccord Genuity Group upped their price target on Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a report on Friday, February 23rd. Oppenheimer upgraded shares of Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price target on the stock in a research note on Tuesday, January 2nd. Finally, Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research report on Thursday, April 11th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Moderna presently has a consensus rating of “Hold” and an average target price of $126.49.

Insider Transactions at Moderna

In related news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $103.38, for a total value of $1,550,700.00. Following the completion of the sale, the director now owns 2,056,931 shares in the company, valued at $212,645,526.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Moderna news, President Stephen Hoge sold 2,388 shares of the business’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $225,833.16. Following the sale, the president now directly owns 1,515,898 shares in the company, valued at $143,358,473.86. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of $103.38, for a total value of $1,550,700.00. Following the completion of the sale, the director now directly owns 2,056,931 shares in the company, valued at approximately $212,645,526.78. The disclosure for this sale can be found here. Insiders have sold a total of 109,954 shares of company stock valued at $11,533,976 in the last ninety days. 15.70% of the stock is currently owned by company insiders.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $101.41 on Friday. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $144.43. The company has a 50-day moving average price of $100.63 and a 200 day moving average price of $93.64. The company has a market cap of $38.83 billion, a P/E ratio of -8.17 and a beta of 1.62. The company has a quick ratio of 3.36, a current ratio of 3.42 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $1.33. The firm had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.53 billion. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The company’s revenue for the quarter was down 44.9% compared to the same quarter last year. During the same period in the previous year, the business earned $3.61 earnings per share. Research analysts predict that Moderna, Inc. will post -7.51 earnings per share for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.